Intrinsiqq
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc.

CAI

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$7.24B
EPS$8.29
P/E3.04
P/FCF108.16
EV/EBITDA42.50
FCF Yield0.9%
Div. Yield–
Net Debt/FCF–
Caris Life Sciences, Inc. intrinsic value
52-Week Range
$14.55$36.14

Profitability & Returns

Revenue (TTM)

$1.05B

▲ +97.0% YoY

Net Income (TTM)

$96M

▲ +75.8% YoY

Op. Margin

13.35%

▲ +67.9pp YoY

ROIC

13.26%

▲ +100.7pp YoY

Cash Flow & Balance Sheet

FCF (FY)

$67M

▲ +126.4% YoY

Op. Cash Flow (TTM)

$84M

▲ +133.9% YoY

Net Debt

-$370M

Net Cash Position

Cash & Equiv.

$799M

Continue Research

Peers

Services-Medical Laboratories · Pick stocks to compare with CAI

CompareIntrinsic value
GHGuardant Health Inc.
$150.87-1.67%30
VCYTVeracyte Inc.
$24.16+0.67%78
CDNACareDx Inc.
$78.56+2.92%57
BLLNBillionToOne, Inc.
$113.94+1.38%59
CSTLCastle Biosciences, Inc.
$33.22-2.88%40
FLGTFulgent Genetics Inc.
$23.74+27.22%20
GRALGrail, Inc.
$121.44+1.94%40
RDNTRadNet Inc.
$76.00-2.58%39

Held by ETFs

CAI is in 54 US ETFs. The largest of them, with CAI's weight in each:

Caris Life Sciences (CAI) in four numbers

Fair value (earnings)
$4.65
Price $25.23 is 443% above it.
Intrinsic Value
Quality score
71/100
Best check: revenue growth, 50.7%. Weakest: share count change, 744.6%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
3.04
Price to free cash flow 108.16.
Financials

Questions about Caris Life Sciences

Is Caris Life Sciences (CAI) overvalued?

At $25.23, Caris Life Sciences' price is 443% above the $4.65 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 3.04 times earnings and 108.16 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Caris Life Sciences' fair value?

Intrinsiqq's calculator puts Caris Life Sciences' fair value at $4.65 a share. It grows earnings per share 5% a year for 5 years, applies an exit P/E of 17.5, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $3.48. Every input can be changed on the Intrinsic Value tab.

Is Caris Life Sciences a high-quality business?

Caris Life Sciences scores 71 out of 100 on Intrinsiqq's quality score, which makes it a solid business on these measures. The score blends 7 checks computed from SEC filings. Its best check is revenue growth at 50.7%, and its weakest is share count change at 744.6%. The Quality tab shows every check against its target.

Does Caris Life Sciences (CAI) pay a dividend?

No. Caris Life Sciences (CAI) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Over the last twelve months it returned cash through share buybacks instead, equal to a 0.4% buyback yield. The Dividends tab shows its cash returns.

Source: 10-Q filed 2 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in CAI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CAI

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.